Four expert-led educational events with Allergan Medical Institute (AMI), Science of AgingTM and Allergan Aesthetics (AA) Global Medical Affairs
AMI symposia will focus on a new Allergan Aesthetics (AA) Signature Program and celebrate 10 years of MD Codes™, with live injection sessions and fireside chat with world-renowned plastic surgeon Dr. Maurício de Maio
Eleven E-Poster data presentations and Meet the Expert sessions with Global experts live from the Allergan Aesthetics booth
NORTH CHICAGO, Ill., March 24, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, demonstrates how to elevate the patient experience and achieve optimal treatment outcomes with new AA Signature program at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from Thursday, March 27– Saturday, March 29, 2025.
Activities will center around the new AA Signature program - an innovative approach to treatment planning harnessing the power of Allergan Aesthetics advanced portfolio to address different patient needs, including Lift, Definition and Skin Quality, and a celebration of 10 years of MD Codes™, which has revolutionized aesthetic medicine with innovative methodology to guide injectors' technique and elevate patient outcomes.
AMI Symposia Meetings will take place as follows:
Design your patients' look with the NEW Signature approach by Allergan Aesthetics. 11.15 AM – 1:15 PM on Thursday, March 27 in the Salle des Princes, Grimaldi Forum.
MD Codes™ and Allergan Aesthetics: a decade of excellence and a signature of success for the future. 9:45 AM– 12:45 PM on Friday, March 28 in the Salle des Princes, Grimaldi Forum.
The first AMI symposium, 'Design your patients' look with the NEW Signature approach by Allergan Aesthetics', will include:
Two key signature looks from the AA Signature program - 'Lift Up' and 'Distinct Definition'.
The meeting will be co-chaired by leading experts Dr. Stefania Roberts (ANZ) and Dr. Andre Braz (Brazil), who'll facilitate discussions and live injections sessions with Dr. Sylwia Lipko-Godlewska (Poland), Dr. Marcel Vinicius (Brazil) and Dr. Lu Wang (China).
Day two will open with 'MD Codes™ and Allergan Aesthetics: a decade of excellence and a signature of success for the future'. Highlights will include:
A deep dive into MD Codes™, its global presence and impact led by Dr. Maurício de Maio (Brazil), Dr. Nelson Chang (China), Dr. Iman Nurlin (Sweden), Dr. Sylwia Lipko-Godlewska (Poland) and Dr. Marcel Vinicius (Brazil).
Expert speakers, live injection sessions and a fireside chat with Dr. Maurício de Maio who will explore the ongoing significance of hyaluronic acid as a key component in the modern multimodal treatment approach.
Beyond the AMI Symposia Events will take place as follows:
Science of AgingTM Symposium. 4:30 PM – 6:30 PM on Thursday, March 27 in the Auric Room, Grimaldi Forum.
Global Aesthetics Medical Affairs Symposium. 2:00 PM – 4:00 PM on Friday, March 28 in the Pinède1 room, Diaghilev level, Grimaldi Forum.
ExclusiveScience of AgingTM Symposium: 'Bold scientific advances for a new age' brings together world-class experts to present the bold scientific advances within the field of aging. Dr. Stephanie Manson Brown, Vice President of R&D, Head of Clinical Development at Allergan Aesthetics, and Dr. Patricia Ogilvie (Germany) will open the event, followed by the discussion of key topics including skin longevity, genomics of aging, epigenetics of skin and mitraclock with Dr. Anne Chang from Stanford University (US), Dr. Howard Jacob from AbbVie (US) and Dr. Cristiana Banila of Mitra Bio (UK). The event will conclude with an engaging Q&A led by event chair Dr. Patricia Ogilvie.
Global Aesthetics Medical Affairs Symposium: 'Socially Transformative Aesthetic Medicine Impacting Emotion and Social Perception' will explore the multidimensional aspects of aesthetic medicine, and how aesthetic treatments not only enhance physical appearance but can also significantly impact emotional well-being and social perception. Chaired by Dr. Steven Dayan (US) alongside Dr. Sarah Boxley (Australia), Dr. Mitchell Brin (US), Prof. Dr. Dario Bertossi (Italy), and Dr. Ligia Colucci (Brazil), the expert panel will discuss the scientific data and provide clinical insights with transformative patient stories.
Meet the Experts Meet the Experts sessions will be live from the Allergan Aesthetics booth, showcasing:
AA Signature – Delivering a 360 approach to skin quality with Dr. Marion Runnebaum, Germany.
Defining the lower face: The AA Signature Distinct Definition approach with Dr. Wenjin Wang, China.
Celebrating 10 years of the MD Codes: Shaping your practice and treatment approach with Dr. Raafat Lakis, Dubai and Dr. Sheila Mulatti, Brazil.
Optimising periorbital treatment to target aging effects: The Eye IMPACT study with Dr. Sarah Boxley, Australia.
Across three days, the Allergan Aesthetics immersive booth (P3) will be a discovery hub for exploring the new AA Signature Program, where visitors can get hands-on with the portfolio, meet industry experts, experience the latest innovation in AA digital applications, and sign up to AMI Digital World.
E-Poster Sessions Allergan Aesthetics' commitment to driving industry with advancing science and clinical data is demonstrated with the acceptance of 11 E-posters. The E-Posters will showcase the latest data and science supporting Allergan Aesthetics brand portfolio, looking specifically at the Skin Quality Lexicon and the multimodal approach of the Eye Impact Study.
Titles and named authors for the 11 posters to be showcased at AMWC:
Presentation Topic
Poster Title
Authors
HArmonyca Int'l Study - Interim ABS
An International, Multicenter, Evaluator-blinded, Randomized, Parallel-Group, Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation
Andreas Nikolis, Nestor Demosthenous, Shannon Humphrey, Fernando Urdiales, Malka Salomon, Andrew Schumacher
HArmonyca MDR Final ABS AMWC Monaco
Prospective, Open-label, Post Marketing Study of the Safety and Effectiveness of HArmonyCa Injectable Gel for Mid Face Soft Tissue Augmentation
Alessandro Gritti, Andrew Schumacher, Malka Salomon, Graeme Kerson
SQ Attribute Definitions Part 2 ABS
Establishing a Vocabulary for Skin Quality: Working Toward Consensus Skin Attribute Definitions From the Patient and Physician Perspective
Psychosocial Impact of Masseter Muscle Prominence: Patient Perspectives Across Multiple Regions
Catherine Foley, Julia Garcia, Martha Gauthier, Greg J Goodman, Shannon Humphrey, Taro Kono, Elisabeth Lee, Grace Pan, Yan Wu
Platysma Integrated Ph3 PRO 309/310 AMWC Monaco 2025 ABS
OnabotulinumtoxinA for the Treatment of Platysma Prominence: Patient-Reported Outcomes From 2 Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled Studies
Joely Kaufman, William P. Coleman, Amir Moradi, Steven Dayan, Patricia Ogilvie, Ava Shamban, Steve Yoelin, Warren Tong, Sandhya Shimoga
Platysma Ph3 323 OL Extension AMWC Monaco 2025 ABS
Repeat Treatments of Moderate to Severe Platysma Prominence With OnabotulinumtoxinA Has a Favorable Safety Profile in a Long-term, Phase 3, Open-label Extension Study
Terrence Keaney, Kenneth Beer, William Hanke, Ira Papel, Deanne Mraz, Rodney Rohrich, Susan Weinkle, Steven Yoelin, Warren Tong, Rene Hopfinger
Platysma Ph3 323 OL PRO AMWC Monaco 2025 ABS
Patient-Reported Outcomes Across Repeat Treatments for Moderate to Severe Platysma Prominence in a Long-term, Phase 3, Open-label Extension Study
Shannon Humphrey, Sue Ellen Cox, Roy Geronemus, Terrence Keaney, Deanne Mraz, Jennifer Nash, James Pehoushek, Rodney Rohrich, Rene Hopfinger, Sandhya Shimoga
Development of the Natural Look Satisfaction Scale for the Treatment of Upper Facial Lines With Neurotoxin
Tanya Brandstetter, Annaliza Dominguez, Julia Garcia, Julie Whyte, Martha Gauthier, Kian Karimi, Steve Yoelin, Carmen Kavali
Vycross Botox Eye Impact - Upper / Midface Tx ABS
Improving Infraorbital Hollow Severity and Volume Through Mid- and Upper-Face Treatment With Hyaluronic Acid (HA)-Fillers and OnabotulinumtoxinA
Gregory J Goodman, Samira Baharlou, Sarah Boxley, Pierre Cuvelier, Cara McDonald, Joan Vandeputte, Ivar Van Heijningen, Julia Garcia, Traci Baker, Smita Chawla, Carola de la Guardia, Frank Lin
Vycross Botox Eye Impact PRO ABS
Improvements in Age Perception and Psychological Well-Being After Rejuvenation of the Eye Area Using Hyaluronic Acid-Based Fillers and OnabotulinumtoxinA in the Mid- and Upper-Face
Gregory J Goodman, Samira Baharlou, Sarah Boxley, Pierre Cuvelier, Cara McDonald, Joan Vandeputte, Ivar Van Heijningen, Julia Garcia, Traci Baker, Smita Chawla, Carola de la Guardia, Frank Lin
Vit C&E after Picosecond Laser Treatment
Improvement in Skin Quality Using Vitamin C+E Complex Antioxidant Serum After Picosecond Laser Treatment
Yang Qui, Caroline Aguilar, Johnny Chen, Kate Huang, Elizabeth T. Makino, Monica Zhu, Huangde Li
Notes to Editors
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter), and YouTube
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Global Media:
Michael Salzillo
michael.salzillo1@allergan.com
U.S. Media:
Adelle Infante
Adelle.infante@allergan.com
Investors:
Liz Shea
liz.shea@abbvie.com
*AA Signature, by Allergan Aesthetics, is a new program that Internationally in February 2025 and will be considered for roll out across International markets, as appropriate, over the next year.
